| Ytd | -19.20% | |
| 1y | -66.21% |
| Open | 1.31 | Prev Close | 1.30 | Low | 1.29 | High | 1.31 | Mkt Cap | 348.74M |
| Vol | 297.78K | Avg Vol | 5.02M | EPS | -0.08 | P/E | -16.86 | Forward P/E | -7.15 |
| Beta | 0.23 | Short Ratio | 4.71 | Inst. Own | 27.33% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 1.12 | 200-d Avg | 1.54 | 1yr Est | 5.50 |
AKBA News
CAMBRIDGE, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a bio
HC Wainwright & Co. analyst Matthew Caufield reiterates Akebia Therapeutics (NASDAQ:AKBA) wit
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better th
Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due
CAMBRIDGE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a bio
Akebia Therapeutics NASDAQ: AKBA outlined its commercial priorities for Vafseo, the expected evoluti
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a b
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biop
Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.03 per share versus the Zacks Consen
Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million ; Q1 2026 total net product
CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biop
CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biop
Akebia to Host Conference Call on May 7 at 8:00 a.m. EDT CAMBRIDGE, Mass.
EADSY, AKBA and AMTB have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2026.
Ionis Pharmaceuticals (NASDAQ: IONS - Get Free Report) and Akebia Therapeutics (NASDAQ: AKBA - Get F
CAMBRIDGE, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a
CAMBRIDGE, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a
JPMorgan Chase and Co. lessened its holdings in Akebia Therapeutics, Inc. (NASDAQ: AKBA) by 39.8% du
Akebia Therapeutics (NASDAQ: AKBA) used its R&D Day presentation to outline a strategy centered on e
Assenagon Asset Management S.A. cut its stake in Akebia Therapeutics, Inc. (NASDAQ: AKBA) by 94.2% i
Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease T
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is expected to report earnings for
On Friday morning, 446 companies hit new 52-week lows.
On Tuesday, 838 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
On Monday, 721 companies achieved new lows for the year.
Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly e
Stocks That Hit 52-Week Highs On Wednesday
Stocks Which Set New 52-Week Low Yesterday, Tues., Nov. 20, 2018
Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 19, 2018